John Gilmer is a pharmaceutical chemist with a diverse array of interests encompassing drug properties, mechanisms, and discovery. In 1995, he achieved his PhD in bile acid chemistry at TCD, paving the way for an extensive career in drug development with Unimed PLC, a prominent pharmaceutical R&D company affiliated with TCD and QUB.

John is intrigued by the prospect of redesigning drug types to limit their absorption from the intestine post-oral administration, thereby localizing their impact within the intestine. Notably, his team made a groundbreaking discovery in the realm of aspirin prodrugs, a development poised to advance colorectal cancer metastasis prevention. This achievement culminated in the establishment of the drug development enterprise, Solvotrin Therapeutics.